Company news
Polypid Ltd. (NASDAQ:PYPD) news
Every Polypid Ltd. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results
August 12, 2026
PolyPid's Double Win: D-PLEX₁₀₀ Gains NDA Acceptance and Priority Review, Ahead of Schedule (NASDAQ: PYPD)
July 31, 2026
PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026
July 30, 2026
PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀
July 29, 2026
PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada
July 21, 2026
PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀
June 1, 2026
PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference
May 20, 2026
PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results
May 13, 2026
PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026
May 6, 2026
PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Soci...
April 28, 2026
PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026
April 13, 2026
PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA
March 31, 2026
PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀’s New Drug Application
March 17, 2026
PolyPid Announces Participation in Upcoming Investor Conferences
February 25, 2026
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
February 11, 2026
PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026
January 28, 2026
PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors
December 16, 2025
PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission
December 3, 2025
PolyPid to Participate in ROTH Capital Partners Virtual KOL Event on December 10, 2025
November 25, 2025
PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results
November 12, 2025
PolyPid's D-PLEX₁₀₀ Wins BioTech Breakthrough Award for "Therapeutics Solution of the Year"
November 6, 2025
PolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025
October 29, 2025
PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress
September 30, 2025
PolyPid to Present at Lytham Partners Fall 2025 Investor Conference and Participate in 4th Annual ROTH Healthcare Opportunities Conference
September 17, 2025
PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX₁₀₀
September 16, 2025
PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference
September 3, 2025
PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference
September 2, 2025
PolyPid : Investor Presentation (3e767d)
August 14, 2025
PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results
August 13, 2025
PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer
August 12, 2025
PolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025
July 30, 2025
PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market
July 15, 2025
PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results
June 16, 2025
PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site In...
June 9, 2025
PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025
June 6, 2025
PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025
May 20, 2025
PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results
May 14, 2025
PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025
April 29, 2025
PolyPid to Participate in The Citizens Life Sciences Conference
April 22, 2025
PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal ...
March 11, 2025
PolyPid to Participate in the 37th Annual ROTH Conference
March 3, 2025
PolyPid Ltd. to Present at the Q1 Investor Summit Virtual Conference on March 11th, 2025
February 27, 2025
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results
February 12, 2025
PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
January 30, 2025
PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025
January 29, 2025
PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a C...
December 23, 2024
PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy
December 11, 2024
PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance
November 29, 2024
PolyPid Provides Corporate Update and Reports Third Quarter 2024 Financial Results
November 13, 2024
PolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select Conference
November 7, 2024